Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year

Reuters2026/08/19 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Humacyte reported peer-reviewed one-year Phase 3 V007 trial results for its acellular tissue engineered vessel in The Lancet Digital Health.
Findings were previously presented at major medical conferences, showing the device outperformed autogenous fistulas for dialysis access at one year.
Benefits were strongest in higher-risk patients, including all women plus men with obesity and diabetes, groups with higher fistula failure rates.
Humacyte plans to file a supplemental Biologics License Application in 2H 2026 to expand Symvess into hemodialysis access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190800PRIMZONEFULLFEED9812468) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year

You may also like

Crypto prices